CAR+ T-Cell Lymphoma after Cilta-cel Therapy for Relapsed or Refractory Myeloma
The Royal Melbourne Hospital · The University of Melbourne · +14 more institutions
Abstract
-mutated T cells, followed by acquisition of further oncogenic genomic variants. Other potential contributors include germline genomic variation, viral infections, and previous treatment for myeloma. In the absence of direct evidence, the contribution of insertional mutagenesis to the development of T-cell lymphoma is currently unclear. (Funded by Johnson & Johnson and Legend Biotech USA; CARTITUDE-4 ClinicalTrials.gov number, NCT04181827.).
Citation impact
- FWCI
- 52.92
- Percentile
- 100%
- References
- 23
Authors
45- SJSimon J. HarrisonCorresponding
The Royal Melbourne Hospital, The University of Melbourne, Peter MacCallum Cancer Centre
- CTCyrille Touzeau
Inserm, Centre Hospitalier Universitaire de Nantes, Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers, Institut National du Cancer, Université d'Angers, Nantes Université
- NKNicolas Kint
Ghent University Hospital, Universitair Ziekenhuis Brussel
- KLKatherine Li
Johnson & Johnson (United States)
- TNTamia Nguyen
The University of Melbourne, Peter MacCallum Cancer Centre
Topics & keywords
- Refractory (planetary science)
- Lymphoma
- Medicine
- Oncology
- Cancer research
- Multiple myeloma
- Internal medicine
- Biology
- Good health and well-being